ITALY - Lay Line Genomics attracts private equity interest
Biopharmaceutical company Lay Line Genomics has reached an exclusive licensing agreement with Dutch biotech group PanGenetics for the development of the antibody Hu-alphaD11, a product with similar analgesic properties to those of morphine but less agressive to the human body.
More on Expansion
Blackstone takes minority stake in Groupe Premium
Deal values French wealth manager at EUR 1.15bn after earlier full exit attempt saw Eurazeo target EUR 1.5bn
e-Attestations aims to triple size with new Keensight backing
Keensight is investing in the risk management platform via its EUR 1bn fifth fund, which closed in 2019
The Bolt-Ons Digest - 3 July 2023
Unquoteтs selection of the latest add-ons with Palatine's Anthesis, Nordic Capital's Regnology, Waterland's Janssen and more
The Bolt-Ons Digest - 26 May 2023
Unquoteтs selection of the latest add-ons with H&F's TeamSystem, Nordic Capital's Regnology, 3'i's Dutch Bakery and more
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds